VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement (Q63865844)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

title

VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

T Schalekamp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

B P Brassé

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

J F M Roijers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

E van Meegen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

F J M van der Meer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

E M van Wijk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

A de Boer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

language of work or name

English

0 references

publication date

27 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

23 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

185-193

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens

23 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Clinical consequences of cytochrome P450 2C9 polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Pharmacogenetics of oral anticoagulants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Pharmacogenetics of oral anticoagulants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Identification of the gene for vitamin K epoxide reductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Effects of CYP2C9 polymorphisms on phenprocoumon anticoagulation status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Determination of bleeding risk using genetic markers in patients taking phenprocoumon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Clinically important drug interactions with anticoagulants. An update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100036

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100036

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192772%20AND%20SRC:MED&resulttype=core&format=json